Multiple studies highlight progress in understanding and treating neurodegenerative diseases. New data suggest that amyloid-clearing Alzheimer’s drugs from Eli Lilly and Eisai have amplified benefits over time. Synthetic cannabinoid analogue INM-901 demonstrated positive effects in an Alzheimer’s mouse model. Research implicates CHI3L1 and endoplasmic reticulum oxidoreductase 1-alpha as contributors to Alzheimer’s pathology. A multi-proteomic analysis unraveled host risks in varicella-zoster virus infections. Dutch biotech NewAmsterdam Pharma presented data linking a cholesterol drug to reduced dementia risk.